MENIERE'S DISEASE

All Classes (Updated 11/29/2023)

DISEASE/CONDITION	EVALUATION DATA	DISPOSITION
A. Previously reviewed	If the AME can determine there have been no	
and warned by the FAA.	further symptoms or episodes of vertigo:	ISSUE
	Note: The medical certificate should not be issued for any class until condition is fully resolved and reviewed by the FAA.	If continued asymptomatic, annotate this information in Block 60.
	Pilot duties must be discontinued while symptomatic or on medication for vertigo.	If return of symptoms, DEFER and submit the most recent ENT evaluation.
B. The FIRST time the	After a recovery period of six (6) months	
condition is reported to the FAA.	 showing: Control of vertigo; No further vertiginous attacks: AND Hearing remains within standards. Submit the following for FAA review:	DEFER Submit the information to the FAA for a possible Special
	1. Current (performed within the past 90 days), detailed clinical otolaryngologist (ENT) evaluation and progress note that documents sustained control and no recurrence of symptoms. It must address if active disease exists. If in remission, when did remission commence.	Follow up Issuance Will be per the Authorization Letter
	2. Current (performed within the past 90 days) clinical audiogram with Air-Conduction/Bone-Conduction (AC/BC) and Speech Discrimination (SD).	
	 3. Typed personal statement describing the history of the condition. It must include: If there is any family history; If single side or bilateral; Episodes of hearing loss over the last year; 	

DISEASE/CONDITION	EVALUATION DATA	DISPOSITION
	 The number of attacks; A description of the severity of the attacks with type of symptoms; Any history of migraine or drop attacks (collapsing suddenly without fainting); Medication used for control/treatment given; Any surgery; Success of control (e.g., How often do you have a recurrence? When was most recent episode?); and Therapy/medication used for control. 4. Additional tests such as (ECOG, VEMP, MRI with Gadolinium of the cerebellopontine angle [CPA], etc.) performed as clinically indicated. 5. All treatment records associated with diagnosis. Note: Pilot and safety related duties (SRD) duties must be discontinued while on medication for vertigo. 14 CFR 61.53 applies. Medication: Betahistine (Serc, Beta-Serc) is 	
C. With associated hearing loss.	NOT allowed. If there is associated hearing loss, the individual should be evaluated to determine if they meet hearing standards. See Item 49. Hearing.	DEFER Submit the information to the FAA